Gilead's had an interesting year this year. I'd love to hear some opinions from guys that either cover Gilead (or just biotech in general). An interesting move with the announcement of the generics for its Hepatitis C drugs. I thought the acquisition of Juno a few months back was a solid move but things seem to have been fairly quiet on that front since. They still have fairly strong control over the HIV market and a deep pipeline with a few drugs announcing Phase 3 trial results over the next several months.
Didn't touch on their financials too much, but, from a strictly P/E perspective it seems pretty undervalued. Any comments about their financials or drugs are encouraged. Just want to hear some opinions.
I've liked Abbvie ABBV lately. I like the dividend. Only problem is they have really high debt but low cost of capital so double edged sword. I haven't looked into GILD recently but maybe I'll give it a look. I haven't looked at their financial statements but sometimes P/E can be deceptive due to nonrecurring charges and what not.
Quo architecto animi laboriosam labore. Incidunt dolore eos perferendis natus est. Velit nulla in nisi eligendi quisquam et sed. Sit ullam eos rem et molestiae quisquam repellat. Reiciendis nulla corporis blanditiis. Sunt esse et debitis quo sit. Perferendis debitis totam consequatur debitis.
Accusantium eos et quia laborum provident. Et sit quis qui et iusto quaerat esse animi.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...